Experimental Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Experimental Physiology 78.2 pp 183-196
© The Physiological Society 1993
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alam, A.
Right arrow Articles by Zaidi, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alam, A.
Right arrow Articles by Zaidi, M
Experimental Physiology, Vol 78, Issue 2, 183-196
Copyright © 1993 by The Physiological Society

Article

Amylin inhibits bone resorption by a direct effect on the motility of rat osteoclasts

AS Alam, BS Moonga, PJ Bevis, CL Huang, and M Zaidi

We have performed a set of independent studies on the effects of the circulating pancreatic polypeptide, amylin, on rat osteoclast function, in vitro. Time-lapse video observations, measuring cell protrusions and retraction, showed that 250 nmol l-1 amylin or 250 nmol l-1 beta-calcitonin gene-related peptide (beta-CGRP) inhibited osteoclast motility (quiescence or Q effect). Both amylin and beta-CGRP produced inhibitory responses with a significant first-order regression over time (half-times, 19 and 28 min respectively). In contrast, 250 nmol l-1 amylin or 250 nmol l-1 beta-CGRP produced no change of osteoclast spread area, whilst 300 pmol l-1 calcitonin (CT) application resulted in cell retraction (R effect). Forskolin (10 mumol l-1) mimicked amylin and CGRP in inhibiting osteoclast motility (half-time, 8.6 min), and similarly lacked an effect on cell spread area. Neither amylin nor beta-CGRP (62.5-1250 nmol l-1) elevated cytosolic free calcium levels ([Ca2+]i) in single osteoclasts whilst 300 pmol l-1 salmon calcitonin (sCT) produced a rapid phasic elevation of [Ca2+]i, confirming previous results with asusuberic (1-7) eel calcitonin. The osteoclast-bone resorption assay revealed the following potency difference in direct comparison of the area of resorption per bone slice: beta-CGRP/amylin, 0.1; sCT/amylin, 800 and human CT/amylin, 12. The potency of deamidated amylin approached that of beta-CGRP. Assay precision ranged between 0.3 and 0.8. Amylin (250 nmol l-1) also significantly (P < 0.05) reduced supernatant (tartrate-resistant) acid phosphatase in the bone-osteoclast cultures. These measures independently indicate an effect of amylin on osteoclast motility through mechanisms distinct from those of calcitonin, possibly through different selectivities for receptor subtypes, the cyclic AMP-linked 'amylin subtype' and the [Ca2+]i-linked 'calcitonin subtype'.


This article has been cited by other articles:


Home page
 Clin Med ResHome page
D. Naot, A. Grey, I. R Reid, and J. Cornish
Lactoferrin - A Novel Bone Growth Factor
Clin. Med. Res., May 1, 2005; 3(2): 93 - 101.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. L. Hull, G. T. Westermark, P. Westermark, and S. E. Kahn
Islet Amyloid: A Critical Entity in the Pathogenesis of Type 2 Diabetes
J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3629 - 3643.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
F. Okamoto, H. Kajiya, H. Fukushima, E. Jimi, and K. Okabe
Prostaglandin E2 activates outwardly rectifying Cl- channels via a cAMP-dependent pathway and reduces cell motility in rat osteoclasts
Am J Physiol Cell Physiol, July 1, 2004; 287(1): C114 - C124.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
I. Villa, C. Dal Fiume, A. Maestroni, A. Rubinacci, F. Ravasi, and F. Guidobono
Human osteoblast-like cell proliferation induced by calcitonin-related peptides involves PKC activity
Am J Physiol Endocrinol Metab, March 1, 2003; 284(3): E627 - E633.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
J. Cornish, K. E. Callon, A. R. King, G. J. S. Cooper, and I. R. Reid
Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice
Am J Physiol Endocrinol Metab, October 1, 1998; 275(4): E694 - E699.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
J. Cornish, K. E. Callon, C. Q.-X. Lin, C. L. Xiao, T. B. Mulvey, D. H. Coy, G. J. S. Cooper, and I. R. Reid
Dissociation of the effects of amylin on osteoblast proliferation and bone resorption
Am J Physiol Endocrinol Metab, May 1, 1998; 274(5): E827 - E833.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
J. Cornish, K. E. Callon, D. H. Coy, N.-Y. Jiang, L. Xiao, G. J. S. Cooper, and I. R. Reid
Adrenomedullin is a potent stimulator of osteoblastic activity in vitro and in vivo
Am J Physiol Endocrinol Metab, December 1, 1997; 273(6): E1113 - E1120.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
K. J. Perry, M. Quiza, D. E. Myers, M. Morfis, G. Christopoulos, and P. M. Sexton
Characterization of Amylin and Calcitonin Receptor Binding in the Mouse {alpha}-Thyroid-Stimulating Hormone Thyrotroph Cell Line
Endocrinology, August 1, 1997; 138(8): 3486 - 3496.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E. Izbicka, T. Yoneda, Y. Takaoka, D. Horn, P. Williams, and G. R. Mundy
Identification of a Novel Bone/Calcium Metabolism-regulating Factor in Porcine Pancreas
J. Biol. Chem., September 20, 1996; 271(38): 23230 - 23234.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by the The Physiological Society.